Search
inhaled anticholinergic agent
Includes:
- ipratropium inhalation
- tiotropium inhalation
Adverse effects:
- increased cardiovascular risk (1.8 vs 1.2%)
- increased risk for arrhythmia in children & young adults [4]
- urinary retention, especially in men with BPH [3]
Interactions
drug interactions
drug adverse effects of parasympatholytics
Specific
ipratropium (Atrovent)
tiotropium (Spiriva, Respimat)
umeclidinium (Incruse Ellipta)
General
aerosolized agent
bronchodilator
parasympatholytic (anticholinergic, antimuscarinic agent)
References
- Singh S et al
Inhaled Anticholinergics and Risk of Major Adverse
Cardiovascular Events in Patients With Chronic Obstructive
Pulmonary Disease: A Systematic Review and Meta-analysis
JAMA 2008;300(12):1439-1450
PMID: 18812535
- Prescriber's Letter 15(11): 2008
Safety of Inhaled Anticholinergics for COPD
Detail-Document#: 241102
(subscription needed) http://www.prescribersletter.com
- Stephenson A et al
Inhaled Anticholinergic Drug Therapy and the Risk of Acute
Urinary Retention in Chronic Obstructive Pulmonary Disease.
Arch Intern Med. 2011;171(10):914-920
PMID: 21606096
http://archinte.ama-assn.org/cgi/content/short/171/10/914
- Singh S, Furberg CD.
Inhaled anticholinergics for chronic obstructive pulmonary
disease: Comment on "Inhaled Anticholinergic Drug Therapy
and the Risk of Acute Urinary Retention in Chronic Obstructive
Pulmonary Disease".
Arch Intern Med 2011; 171(10):920-922
PMID: 21606097
- Journal Watch: Physician's First Watch, May 23, 2012
Massachusetts Medical Society
American Thoracic Society Meeting, May 18-23, 2012,
San Francisco, CA
- Vande Griend JP, Linnebur SA.
Inhaled anticholinergic agents and acute urinary retention
in men with lower urinary tract symptoms or benign prostatic
hyperplasia.
Ann Pharmacother. 2012 Sep;46(9):1245-9. Review.
PMID: 22851743